3 results
Approved WMOPending
To investigate the long-term safety, tolerability and acceptability of Nasalfent in the treatment BTCP
Approved WMOCompleted
The primary safety endpoint is to evaluate a 30-day major adverse event (MAE) rate, where MAE is a composite of the following device- or procedure-related events: * All-cause mortality* Stroke* Life-threatening bleeding (MVARC scale)* Major vascular…
Approved WMOCompleted
The main purpose of this pilot study is to investigate the feasibility of fluorescence imaging using cetuximab-IRDye800CW for intraoperative margin assessment in patients with cutaneous squamous cell carcinoma.